Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Gains from Investment Securities (2016 - 2025)

Firefly Neuroscience has reported Gains from Investment Securities over the past 14 years, most recently at $15000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $15000.0 for Q4 2025, down 96.81% from a year ago — trailing twelve months through Dec 2025 was $15000.0 (down 96.81% YoY), and the annual figure for FY2025 was $15000.0, down 96.81%.
  • Gains from Investment Securities for Q4 2025 was $15000.0 at Firefly Neuroscience, down from $464939.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for AIFF hit a ceiling of $715000.0 in Q3 2023 and a floor of -$9.0 in Q2 2022.
  • Median Gains from Investment Securities over the past 5 years was $203416.5 (2021), compared with a mean of $259726.3.
  • Biggest five-year swings in Gains from Investment Securities: soared 2625.0% in 2021 and later plummeted 100.0% in 2022.
  • Firefly Neuroscience's Gains from Investment Securities stood at $302500.0 in 2021, then tumbled by 56.63% to $131200.0 in 2022, then grew by 2.39% to $134333.0 in 2023, then skyrocketed by 249.92% to $470061.0 in 2024, then tumbled by 96.81% to $15000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $15000.0 (Q4 2025), $464939.0 (Q3 2025), and $15000.0 (Q2 2025) per Business Quant data.